Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | QPCT | Q16769 | 4/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28294180 | 0.88 | MMP12 (0.69) | MMP12CLK4QPCTMAP4K4QPCTL | |
| SCHEMBL28292532 | 0.86 | MMP12 (0.60) | MMP12DYRK1AQPCTMAP4K4XDH | |
| SCHEMBL2096516 | 0.85 | QPCT (0.42) | MMP12QPCTQPCTLALDH1A1 | |
| SCHEMBL225931 | 0.82 | MMP12 (0.73) | MMP12QPCTALDH1A1LMNATSHR | |
| SCHEMBL29919790 | 0.82 | MMP12 (0.73) | MMP12QPCTALDH1A1LMNATSHR | |
| SCHEMBL6008269 | 0.80 | MAPT (0.50) | MMP12QPCTXDHQPCTLALDH1A1 | |
| SCHEMBL31143361 | 0.80 | MAPT (0.50) | MMP12QPCTXDHQPCTLALDH1A1 | |
| SCHEMBL13373333 | 0.80 | MAPK14 (0.47) | QPCTMAP4K4QPCTL | |
| SCHEMBL22418755 | 0.79 | QPCT (0.47) | CLK4DYRK1AQPCTQPCTLALDH1A1 | |
| SCHEMBL2457365 | 0.79 | QPCT (0.50) | CLK4DYRK1AQPCTQPCTLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107312008-B | A kind of catalysis prepares the catalyst and system and method for benzimidazole simultaneously [2,1-b] quinoline -6- ketone derivatives | 马鞍山市泰博化工科技有限公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-106866543-B | A method of benzimidazole compound is catalyzed and synthesized under microwave radiation in water phase | 福建医科大学 | 2019-05-14 | — | — | CN | disclosed |
| CN-107312008-A | A kind of easy catalysis prepares the catalyst and system and method for benzimidazole simultaneously ketone derivatives of [2,1 b] quinoline 6 | 马鞍山市泰博化工科技有限公司 | 2017-11-03 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MMP12 3540/4885CLK4 3049/4885DYRK1A 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.